...
【24h】

Targeting dendritic cells--why bother?

机译:靶向树突状细胞-为什么要打扰?

获取原文
获取原文并翻译 | 示例

摘要

Vaccination is among the most efficient forms of immunotherapy. Although sometimes inducing lifelong protective B-cell responses, T-cell-mediated immunity remains challenging. Targeting antigen to dendritic cells (DCs) is an extensively explored concept aimed at improving cellular immunity. The identification of various DC subsets with distinct functional characteristics now allows for the fine-tuning of targeting strategies. Although some of these DC subsets are regarded as superior for (cross-) priming of naive T cells, controversies still remain about which subset represents the best target for immunotherapy. Because targeting the antigen alone may not be sufficient to obtain effective T-cell responses, delivery systems have been developed to target multiple vaccine components to DCs. In this Perspective, we discuss the pros and cons of targeting DCs: if targeting is beneficial at all and which vaccine vehicles and immunization routes represent promising strategies to reach and activate DCs.
机译:疫苗接种是免疫治疗的最有效形式之一。尽管有时会诱导终身保护性B细胞反应,但T细胞介导的免疫仍然具有挑战性。将抗原靶向树突状细胞(DC)是旨在改善细胞免疫力的广泛探索的概念。现在,通过识别具有不同功能特征的各种DC子集,可以对定位策略进行微调。尽管这些DC亚组中的一些被认为比原始T细胞的(交叉)启动更优越,但是关于哪个亚组代表免疫治疗的最佳靶标仍有争议。由于仅靶向抗原可能不足以获得有效的T细胞反应,因此已开发出将多种疫苗成分靶向DC的递送系统。在此“观点”中,我们讨论了靶向DC的利弊:靶向完全有益,以及哪种疫苗载体和免疫途径代表达到并激活DC的有前途的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号